4D Molecular Therapeutics, Inc. short interest in 2021
In 2021, 4D Molecular Therapeutics, Inc.'s disclosed short interest ran from 1.73% of shares outstanding on 15 Mar 2021 to 4.35% on 31 Dec 2021, a change of +2.62 percentage points. The year's high was 6.02% on 15 Oct 2021 and its low 1.73% on 15 Mar 2021, averaging 3.74% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.39 days on 30 Jul 2021. Full history: 4D Molecular Therapeutics, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2021 in figures
- Start of year
- 1.73% (15 Mar 2021)
- End of year
- 4.35% (31 Dec 2021)
- Change
- +2.62 pp
- High
- 6.02% (15 Oct 2021)
- Low
- 1.73% (15 Mar 2021)
- Average
- 3.74%
- Highest days to cover
- 13.39 (30 Jul 2021)
- SEC filings marked
- 8
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Mar 2021 | 1.73% | 2.95 | |
| 31 Mar 2021 | 2.81% | 2.79 | 10-K filed, results (8-K) |
| 15 Apr 2021 | 2.55% | 7.16 | |
| 30 Apr 2021 | 3.10% | 9.63 | |
| 14 May 2021 | 3.06% | 6.44 | 10-Q filed, results (8-K) |
| 28 May 2021 | 3.31% | 7.96 | |
| 15 Jun 2021 | 3.77% | 8.82 | |
| 30 Jun 2021 | 3.55% | 3.81 | |
| 15 Jul 2021 | 3.73% | 8.58 | |
| 30 Jul 2021 | 3.74% | 13.39 | |
| 13 Aug 2021 | 3.78% | 11.88 | 10-Q filed, results (8-K) |
| 31 Aug 2021 | 3.87% | 8.36 | |
| 15 Sep 2021 | 4.57% | 7.96 | |
| 30 Sep 2021 | 5.94% | 5.14 | |
| 15 Oct 2021 | 6.02% | 12.86 | |
| 29 Oct 2021 | 5.94% | 3.37 | |
| 15 Nov 2021 | 3.68% | 4.72 | 10-Q filed, results (8-K) |
| 30 Nov 2021 | 2.74% | 3.50 | |
| 15 Dec 2021 | 2.65% | 3.44 | |
| 31 Dec 2021 | 4.35% | 2.62 |
See also: 4D Molecular Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.